Jonathan R. Malkin
Gründer bei ATP Capital LP
Ursprung des Netzwerks ersten Grades von Jonathan R. Malkin
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
ATP Capital LP
ATP Capital LP Real Estate DevelopmentFinance ATP Capital LP provides real estate investment and management services. The company was founded by Jonathan R. Malkin in 1997 and is headquartered in Clearwater Beach, FL.
1
| Private Company | Real Estate Development | 1 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Jonathan R. Malkin
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
RESPONSE BIOMEDICAL CORP | Miscellaneous Commercial Services | Chairman | |
Emergent Product Development Seattle
Emergent Product Development Seattle Pharmaceuticals: MajorHealth Technology Emergent Product Development Seattle discovers and develops biopharmaceutical products. It focuses on the discovery and development of novel medicines to treat inflammatory diseases and cancer. The company was founded by Peter A. Thompson, Jeffrey A. Ledbetter and Kendall M. Mohler in March 1999 and is headquartered in Seattle, WA. | Pharmaceuticals: Major | Chief Executive Officer | |
ANTHERA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
OcuNexus Therapeutics, Inc.
OcuNexus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology OcuNexus Therapeutics, Inc. develops and commercializes therapeutic products for wound care and tissue repair. The firm offers Nexagon, an oligonucleotide that downregulates the gap junction in tissue repair. Its Nexagon also reduces lesion spread, swelling, inflammation, scarring, and time to wound closure in various tissue types, including the eye, skin, spinal cord, nerve, and brain. The company was founded in 2005 by David Lawrence Becker, Colin C. Green and Bradford J. Duft and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Director/Board Member | |
Cardioxyl Pharmaceuticals LLC
Cardioxyl Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cardioxyl Pharmaceuticals, Inc. discovers and develops therapies and technologies for the treatment of cardiovascular diseases. It offers nitroxyl therapeutics, including CXL-1020, a nitroxyl donor compound for the intravenous treatment of acute decompensated heart failure and nitroxyl donor compounds for unmet medical needs in other cardiovascular indications. The company was founded by Vincent J. Kalish and Douglas Cowart in 2005 and is headquartered in Chapel Hill, NC. | Pharmaceuticals: Major | Director/Board Member | |
PRINCIPIA BIOPHARMA INC. | Pharmaceuticals: Major | Chairman | |
CORVUS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Founder | |
Brown University | College/University | Undergraduate Degree | |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | College/University | Corporate Officer/Principal | |
Newyu, Inc.
Newyu, Inc. Medical/Nursing ServicesHealth Services Newyu, Inc. provides web-based health information services. It offers implementation, ongoing account management and customer support services. The company serves those monitoring asthma, diabetes, pulmonary disease, hypertension, cardiovascular disease and congestive heart failure. iMetrikus was founded by William J. Rutter in 1998 and is headquartered in Carlsbad, CA. | Medical/Nursing Services | Chief Executive Officer | |
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Pharmaceuticals: Major | Director/Board Member | |
MIRATI THERAPEUTICS | Biotechnology | Director/Board Member | |
BD Biosciences, Systems & Reagents, Inc.
BD Biosciences, Systems & Reagents, Inc. Pharmaceuticals: MajorHealth Technology BD Biosciences, Systems & Reagents, Inc. provides tools and solutions to research and clinical laboratories in basic research, drug discovery, development, biopharmaceutical production and disease management. The company was founded on May 9, 1991 and is headquartered in San Jose, CA. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | Investment Managers | Private Equity Investor | |
Becton Dickinson Immunocytometry Systems
Becton Dickinson Immunocytometry Systems Medical SpecialtiesHealth Technology Part of Becton, Dickinson & Co., Becton Dickinson Immunocytometry Systems manufactures medical instruments. The company is based in San Jose, CA. | Medical Specialties | Chief Tech/Sci/R&D Officer | |
Adaptimmune Ltd.
Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom. | Medical/Nursing Services | Director/Board Member | |
Strategicon Partners | Founder | ||
Cleave Therapeutics, Inc.
Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | Biotechnology | Founder | |
The Warren Alpert Medical School | College/University | Doctorate Degree | |
OxOnc Development LP
OxOnc Development LP BiotechnologyHealth Technology OxOnc Development LP operates as an oncology development company. It offers a drug development model that is based on the expertise and core competencies to design and execute clinical trials in oncology. The firm's business model is an integration of scientific, clinical, operational and financial resources, and provides a value-add proposition to its co-development partner by providing a profit and loss-sparing mechanism to fund research and development efforts externally. The company was founded in 2012 and is headquartered in George Town, Cayman Islands. | Biotechnology | Director/Board Member | |
SYNTHORX, INC. | Biotechnology | Director/Board Member | |
PMV PHARMACEUTICALS, INC. | Miscellaneous Commercial Services | Director/Board Member | |
DECIBEL THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
ReCode Therapeutics, Inc.
ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX. | Pharmaceuticals: Major | Director/Board Member | |
ALPINE IMMUNE SCIENCES, INC. | Biotechnology | Director/Board Member | |
PREVAIL THERAPEUTICS INC. | Biotechnology | Director/Board Member | |
EDGEWISE THERAPEUTICS, INC. | Biotechnology | Founder | |
JANUX THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Angel Pharmaceuticals Co., Ltd.
Angel Pharmaceuticals Co., Ltd. BiotechnologyHealth Technology Angel Pharmaceuticals Co., Ltd. operates as a biopharmaceutical company which develops medicines for treatment of cancer, autoimmune and infectious diseases. The company was founded by Richard Miller and Ted Wang on October 5, 2020 and is headquartered in Shanghai, China. | Biotechnology | Director/Board Member | |
Gennao Bio, Inc.
Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | Pharmaceuticals: Major | Director/Board Member | |
Terremoto Biosciences, Inc.
Terremoto Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Terremoto Biosciences, Inc. is a drug discovery and development company that creates highly targeted, small molecule medicines with unmatched selectivity, potency, and efficacy to deliver superior therapeutic benefit to patients. The company is based in San Francisco, CA. Terremoto is supported by leading investors, including OrbiMed, Third Rock Ventures, EcoR1 Capital, Novo Holdings, and Cormorant Capital. The company aims to expand the universe of drug targets and improve existing medicines by unleashing the power of covalent chemistry. Terremoto was founded by Peter A. Thompson and Matthew P. Jacobson, and Peter A. Thompson has been the CEO since incorporation. | Pharmaceuticals: Major | Founder | |
ARS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
ADAPTIMMUNE THERAPEUTICS PLC | Biotechnology | Director/Board Member |
Statistik
International
Vereinigte Staaten | 33 |
China | 3 |
Vereinigtes Königreich | 3 |
Kanada | 2 |
Cayman Islands | 2 |
Sektoral
Health Technology | 30 |
Consumer Services | 4 |
Commercial Services | 3 |
Health Services | 3 |
Finance | 2 |
Operativ
Director/Board Member | 26 |
Independent Dir/Board Member | 13 |
Founder | 8 |
Chairman | 6 |
Corporate Officer/Principal | 4 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Peter Thompson | 39 |
- Börse
- Insiders
- Jonathan R. Malkin
- Unternehmensverbindungen